Subklinik ve Aşikar Hipotiroid Hastalarda Serum Netrin-1, Nesfatin-1 ve Adropin Düzeylerinin Karşılaştırılması

Yıl 2026, Cilt: 13 Sayı: 1 , 30 - 37 , 29.04.2026

Emine Gemci , Gülhan Akbaba , Neşe Çınar , Tuba Edgünlü , Kursad Tosun

https://izlik.org/JA25SN38GZ

Öz

Netrin-1, nesfatin-1 ve adropin; enerji homeostazı, inflamasyon, kardiyovasküler fonksiyon ve iştah düzenlemesi gibi fizyolojik süreçlerde rol oynayan düzenleyici peptitlerdir. Çalışmamız, aşikâr hipotiroidizm (AH) ve subklinik hipotiroidizm (SH) hastalarında serum netrin-1, nesfatin-1 ve adropin konsantrasyonlarını değerlendirerek; tiroid fonksiyon testleri ve metabolik parametrelerle ilişkilerini incelemek amacıyla tasarlanmıştır. Bu boşluğu ele alarak, araştırmamız bu moleküllerin tiroid ilişkili metabolik düzensizliklerdeki olası rolünün daha iyi anlaşılmasına katkıda bulunmayı amaçlamaktadır. Bu tek merkezli kesitsel çalışma prospektif olarak gerçekleştirilmiştir. Çalışmamıza 27 AH hastası, 29 SH hastası ve 27 kontrol grubu olmak üzere 83 kişi dahil edildi. Vücut kitle indeksi (VKİ), bel çevresi (BÇ), serbest triiodothyronin (sT3), serbest tiroksin (sT4), tiroid stimüle edici hormon (TSH), tiroid peroksidaz antikoru (anti-TPO), tiroglobulin antikoru (anti-TG), açlık kan şekeri (AKŞ), insülin, homeostatik model değerlendirmesi (HOMA-IR), trigliserid (TG), total kolesterol (TOTAL-K), düşük dansiteli kolesterol (LDL-K), çok düşük dansiteli kolesterol (VLDL-K), yüksek dansiteli kolesterol (HDL-K), C reaktif protein (CRP), Netrin-1, Nesfatin-1, Adropin ölçüldü. BKİ, BÇ, TSH, anti-TPO, AKŞ, TOTAL-K ve LDL-K düzeyleri AH grubunda kontrol grubuna göre anlamlı olarak daha yüksekti (sırasıyla p=0,014, p=0,007, p<0,001, p<0,001, p<0,001, p=0,024, p=0,025). Her üç molekül için de gruplar arasında anlamlı bir fark yoktu. Tüm vakalar değerlendirildiğinde, adropin ile TG, TOTAL-C, LDL-C ve VLDL-C arasında bir ilişki vardı (sırasıyla r=-0,314, p=0,007; r=-0,340, p=0,003; r=-0,305, p=0,009; r=-0,381, p=0,001). Hasta grubu için ayrı ayrı yapılan korelasyon analizi, nesfatin-1 ile sT3 arasında bir korelasyon olduğunu ortaya koydu (r=0,360, p=0,015). Bu çalışma, netrin-1, nesfatin-1 ve adropin ile tiroid hormonu regülasyonu arasındaki ilişkiye dair yeni kanıtlar sunması bakımından literatüre özgün bir katkı sağlamaktadır.

Anahtar Kelimeler

Adropin , Hipotiroidizm , Nesfatin-1 , Netrin-1 , Tiroid

Comparing The Levels of Serum Netrin-1, Nesfatin-1 and Adropin in Subclinical and Overt Hypothyroid Patients

https://izlik.org/JA25SN38GZ

Öz

Netrin-1, nesfatin-1, and adropin are regulatory peptides that play significant roles in energy homeostasis, inflammation, cardiovascular function, and appetite regulation. The present study was designed to assess serum concentrations of netrin-1, nesfatin-1 and adropin in patients with overt hypothyroidism (OH) and subclinical hypothyroidism (SH), and to examine their relationships with thyroid function tests and metabolic parameters. This single-center, cross-sectional study was performed prospectively. A total of 83 people: 27 OH patients, 29 SH patients and 27 control group were included in our study. Body mass index (BMI), WC (waist circumference), free triiodothyronine (fT3), free thyroxine (fT4), thyroid stimulating hormone (TSH), anti-thyroid peroxidase (anti-TPO), anti thyroglobulin (anti-TG), fasting blood glucose (FBG), insülin, homeostatic model assessment of insulin resistance (HOMA-IR), triglyceride (TG), total cholesterol (TOTAL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), high density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), Netrin-1, Nesfatin-1, Adropin were measured. The BMI, WC, TSH, anti-TPO, FBG, TOTAL-C and LDL-C levels were significantly higher in the OH group than in the control group (p=0.014, p=0.007, p<0.001, p<0.001, p<0.001, p=0.024, p=0.025 respectively). There was no significant difference among the groups regarding all three molecules. Considering all cases, there was a relationship between adropin and TG, TOTAL-C, LDL-C and VLDL-C (r=-0.314, p=0.007; r=-0.340, p=0.003; r=-0.305, p=0.009; r=-0.381, p=0.001 respectively). The correlation analysis performed separately for the patient group revealed a correlation between nesfatin-1 and fT3 (r=0.360, p=0.015). This study provides new evidence on the relationship between netrin-1, nesfatin-1, and with thyroid hormone regulation.

Anahtar Kelimeler

Adropin , Hypothyroidism , Nesfatin-1 , Netrin-1 , Thyroid

Etik Beyan

The study is conducted with the approval of Muğla Sıtkı Koçman University Faculty of Medicine Clinical Research Ethics Committee dated 16/03/2017 and numbered 5.

Destekleyen Kurum

The study was supported by the Muğla BAP unit.

Kaynakça

• Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1675.
• Yang N, Yao Z, Miao L, et al. Novel Clinical Evidence of an Association between Homocysteine and Insulin Resistance in Patients with Hypothyroidism or Subclinical Hypothyroidism. PLoS One. 2015;10(5):e0125922.
• Akbaba G, Berker D, Isık S, et al. Changes in the before and after thyroxine treatment levels of adipose tissue, leptin, and resistin in subclinical hypothyroid patients. Wien Klin Wochenschr. 2016;128(15-16):579-585.
• Yuan X, Shen G, Xiao H, et al. Netrin-1 and RGMa: Novel Regulators of Atherosclerosis-Related Diseases. Cardiovasc Drugs Ther. 2025;39(1):211-219.
• Ziegon L, Schlegel M. Netrin-1: A Modulator of Macrophage Driven Acute and Chronic Inflammation. Int J Mol Sci. 2021;23(1):275.
• Toque HA, Fernandez-Flores A, Mohamed R, et al. Netrin-1 is a novel regulator of vascular endothelial function in diabetes. PLoS One. 2017;12(10):e0186734.
• Dore R, Levata L, Lehnert H, et al. Nesfatin-1: functions and physiology of a novel regulatory peptide. J Endocrinol. 2017;232(1):45-65.
• Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-712.
• Feijóo-Bandín S, Rodríguez-Penas D, García-Rúa V, et al. Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level. Endocrine. 2016;52(1):11-29.
• Riva M, Nitert MD, Voss U, et al. Nesfatin-1 stimulates glucagon and insulin secretin and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res. 2011;346(3):393-405.
• Ali II, D'Souza C, Singh J, et al. Adropin’s Role in Energy Homeostasis and Metabolic Disorders. Int J Mol Sci. 2022;23(15):8318.
• Yosaee S, Khodadost M, Esteghamati A, et al. Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects. Am J Mens Health. 2017;11(2):426-434.
• Oruc CU, Akpinar YE, Dervisoglu E, et al. Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome. Clin Chem Lab Med. 2017;55(1):139-144.
• Mogulkoc R, Dasdelen D, Baltaci SB, et al. The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats. Horm Mol Biol Clin Investig. 2020;42(1):37-42.
• Mancini A, Di Segni C, Raimondo S, et al. Thyroid Hormones, Oxidative Stress, and Inflammation. Mediators Inflamm. 2016;2016:6757154.
• Walczak K, Sieminska L. Obesity and Thyroid Axis. Int J Environ Res Public Health. 2021;18(18):9434.
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
• Tiller D, Ittermann T, Greiser KH, et al. Association of Serum Thyrotropin with Anthropometric Markers of Obesity in the General Population. Thyroid. 2016;26(9):1205-1214.
• Svare A, Nilsen TI, Bjøro T, et al. Serum TSH related to measures of body mass: longitudinal data from the HUNT Study, Norway. Clin Endocrinol (Oxf). 2011;74(6):769-775.
• Biondi B, Kahaly GJ, Robertson RP. Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders. Endocr Rev. 2019;40(3):789-824.
• Chaker L, Ligthart S, Korevaar TI, et al. Thyroid function and risk of type 2 diabetes: a population-based prospective cohort study. BMC Med. 2016;14(1):150.
• Laway BA, War FA, Shah S, et al. Alteration of lipid parameters in patients with subclinical hypothyroidism. Int J Endocrinol Metab. 2014;12(3):e17496.
• Tohma Y, Akturk M, Altinova A, et al. Circulating Levels of Orexin-A, Nesfatin-1, Agouti-Related Peptide, and Neuropeptide Y in Patients with Hyperthyroidism. Thyroid. 2015;25(7):776-783.
• Gungunes A, Ozbek M, Ginis Z, et al. Serum nesfatin-1 levels in overt and subclinical hyperthyroidism. Minerva Endocrinol. 2014;39(3):209-214.
• Yang M, Zhang Z, Wang C, et al. Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance. Diabetes. 2012;61(8):1959-1968.
• Liu F, Yang Q, Gao N, et al. Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus. J Diabetes Res. 2014;2014:128014.
• Schalla MA, Stengel A. Current understanding of the role of nesfatin-1. J Endocr Soc. 2018;2(10):1188-1206.
• Stevens JR, Kearney ML, St-Onge MP, et al. Inverse association between carbohydrate consumption and plasma adropin concentrations in humans. Obesity (Silver Spring). 2016;24(8):1731-1740.
• Kumar KG, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012;20(7):1394-1402.
• Soltani S, Beigrezaei S, Malekahmadi M, et al. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies. BMC Endocr Disord. 2023;23(1):73.
• Yu HY, Zhao P, Wu MC, et al. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014;190-191:46-49.